A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

New England Journal of Medicine

Volumn 361, Issue 19, 2009, Pages 1848-1855

  Macdougall, Iain C ^a   Rossert, Jerome ^b,c   Casadevall, Nicole ^d,e   Stead, Richard B ^f   Duliege, Anne Marie ^g   Froissart, Marc ^b,c   Eckardt, Kai Uwe ^h  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e INSERM   (France)

^f BioPharma Consulting Services   (United States)

^g AFFYMAX RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN ANTIBODY; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; ERYTHROPOIESIS; GANGRENE; HUMAN; ISCHEMIC OPTIC NEUROPATHY; KIDNEY DISEASE; LEUKOPENIA; LUNG EDEMA; MULTICENTER STUDY; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RETICULOCYTE COUNT; STATISTICAL ANALYSIS; TREATMENT DURATION; TUBERCULOSIS;

EID: 70350774297     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa074037     Document Type: Article

References (28)

1. Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C, Koch KM, Scigalia P, eds. Erythropoietin: molecular physiology and clinical application. New York: Marcel Dekker, 1993:266-275
2. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996;335:523-524 (Pubitemid 26269960)
3. Gershon SK, Luksenburg H, Coté TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346:1584-1585 [Erratum, N Engl J Med 2002;347:458.]
4. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004;15:398-406. (Pubitemid 38140780)
5. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475 (Pubitemid 34441737)
6. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-1408
7. Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant 2007;22:1462-1464 (Pubitemid 47072237)
8. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998;339:578-583
9. Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004;363:1768-1771 (Pubitemid 38698380)
10. Andrade J, Taylor PA, Love JM, Levin A. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant 2005;20:2548-2551 (Pubitemid 41548887)
11. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002;13:2381-2383 (Pubitemid 34925249)
12. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:458-464
13. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-1311
14. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006;108:1830-1834 (Pubitemid 44394989)
15. Macdougall IC, Tucker B, Yaqoob M, et al. Hematide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), achieves correction of anemia and maintains hemoglobin (Hb) in patients with chronic kidney disease (chronic renal failure) not on dialysis. Presented at the American Society of Nephrology 11th Annual Renal Week, San Diego, CA, November 14-19 2006. abstract.
16. Besarab A, Zeig S, Geronemus R, et al. Hematide, a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated epoetin alfa (erythropoietin). Presented at the National Kidney Foundation Spring Clinical Meeting, Orlando, FL, April 10-14 2007. abstract.
17. Pickering LM, Cwiertka K, Jassem J, et al. Hematide, a synthetic peptide-based erythropoiesis stimulating agent (ESA), assessed for correction of anemia in oncology patients receiving chemotherapy. Blood 2006;108:378a. abstract.
18. Woodburn KW, Fan Q, Winslow S, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007;35:1201-1208 (Pubitemid 47088782)
19. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084 (Pubitemid 44749316)
20. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098 (Pubitemid 44749317)
21. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
22. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630-633 (Pubitemid 26072120)
23. World Health Organization Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, WHO Offset Publication No. 48, 1979.
24. Guideline for industry: clinical safety data management: definitions and standards for expedited reporting. No. ICHE2A. Silver Spring, MD: Food and Drug Administration, March 1995. (Accessed October 9, 2009, at http://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm073087. pdf.)
25. Casadevall N, Rossert J, Swanson S, et al. Anti-erythropoietin antibodies (Abs) not associated with pure red cell aplasia (PRCA), in patients treated with erythropoiesis- stimulating agents (ESAs). J Am Soc Nephrol 2004;15:545A. abstract.
26. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-1681 [Erratum, N Engl J Med 2006;355:2054.]
27. Bromberg ME. Immune thrombocytopenic purpura - the changing therapeutic landscape. N Engl J Med 2006;355:1643-1645 (Pubitemid 44583954)
28. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997;276:1696-1699